If a supplied lot fails agreed specifications, we’ll replace it at no cost or refund its purchase price in full.
Quality test failed? Free replacement or full refund.
Off-spec? Free replacement or full refund.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epithalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
Also known as CJC+IPA 5mg+5mg
GH-axis blend (CJC-1295 no DAC + Ipamorelin)
Supply and ordering
Ask sales about CJC 5mg + IPA 5mg availability, order quantities, packaging, and batch documentation. Include other catalog items in the same inquiry if you are planning a combined or recurring order.
Overview
The CJC-1295 + Ipamorelin combination is one of the most-requested GH-axis blends in the catalog and one of the most-cited dual-pathway formulations in compounding pharmacy and research workflows. The two peptides act on parallel signaling pathways that converge on somatotroph GH release: CJC-1295 (no DAC, the Modified GRF 1-29 form) is a GHRH-receptor agonist mimicking the hypothalamic GHRH input, while Ipamorelin is a selective GHSR (ghrelin receptor) agonist mimicking the alternative ghrelin-pathway input. The dual-pathway combination produces GH-release magnitudes substantially larger than either component alone at comparable individual doses, the synergy is the entire rationale for the combination. PeptideXpo supplies the CJC-1295 + Ipamorelin blend as a co-lyophilized vial to a ≥99.0% HPLC purity specification for each component. The standard ratio is 1:1 by mass (5+5 mg in a 10 mg vial); custom ratios (2+5, 5+10, 10+10) and larger total fills are available through the OEM service. Co-lyophilization is preferred over solution-phase mixing because both components are short-half-life peptides where ratio stability matters operationally and the co-lyophilized form locks the ratio at the lyophilization step. The batch COA reports both component purities individually by HPLC with MS identity; the measured ratio in the released vial is available on request and listed on the COA when tested.
Who buys this, and why
Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.
Primary buyer fit: 503A / 503B compounding pharmacies and medical aesthetic clinics and med spas.
Specifications
Documentation available on request
Each picture is a low-resolution preview of a report's first page, with batch and report numbers covered. For the full, clear report, ask our sales team, naming the product and strength.
Batch COACJC 5mg + IPA 5mg 5 mg + 5 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Third-party reportCJC-1295 + Ipamorelin 5 + 5 mg
HPLC purity · MS identity
Third-party laboratory, Tianjin, China
Full, clear copy from sales
Independent test fails? Full refund. How it works
Regulatory note
Sold as a multi-peptide active for research and for OEM-formulated finished products under the receiving brand's regulatory framework. Blend composition, finished-product safety, labeling claims, and notification responsibilities remain with the brand owner. Request the matching batch COA and agree any component-level analytical data before quotation.
Selected literature
Frequently asked questions
The combination works because the two components engage different receptors that converge on the same target cell type. CJC-1295 (no DAC) activates the GHRH receptor on anterior-pituitary somatotrophs; Ipamorelin activates the GHSR (ghrelin) receptor on the same cells. The two signaling cascades reinforce rather than compete, producing GH-release magnitudes substantially larger than either alone, typically 4-5× larger acute GH pulse at comparable individual doses. For the full pharmacology rationale, ratio considerations, and analytical-packet specifics, see our CJC-1295 + Ipamorelin guide.
Yes, all three are GHRH-receptor agonists and produce mechanistically equivalent dual-pathway combinations when paired with Ipamorelin. The Tesamorelin + Ipamorelin blend (tesa-ipa-blend SKU) is supplied at a 10+5 mg ratio reflecting the higher mass-equivalent dosing typical for Tesamorelin. Sermorelin + Ipamorelin is less common in commercial blends because Sermorelin's shorter half-life is less well-matched to Ipamorelin's pharmacokinetics. The CJC-1295 (no DAC) + Ipamorelin pairing remains the most-requested combination because the half-life profiles complement each other best.
Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.
Related peptides
Modified GRF 1-29 · GHRH analog
Nasal spray available
Ghrelin / GHSR pathway GH-release peptide
Nasal spray available
29-mer
GHRH 1-29 fragment
Nasal spray availableCapsules available
